Komen Foundation Adds International Breast Cancer Programs

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 4
Volume 9
Issue 4

ROME-The Susan G. Komen Breast Cancer Foundation has extended its breast cancer awareness programs internationally with the establishment of affiliates in Italy, Argentina, Germany, and Greece. The Dallas-based foundation has 117 local US affiliates.

ROME—The Susan G. Komen Breast Cancer Foundation has extended its breast cancer awareness programs internationally with the establishment of affiliates in Italy, Argentina, Germany, and Greece. The Dallas-based foundation has 117 local US affiliates.

Riccardo Masetti, MD, assistant professor of surgery, Catholic University, Rome, joined Komen Foundation president Susan Braun in making the announcement of the Italian affiliate via a live webcast from the 5th Annual Multidis-ciplinary Symposium on Breast Diseases.

The kickoff event for the Italian affiliate is an international version of the Foundation’s Race for the Cure, to be held in the gardens of Rome’s Villa Borghese on May 21, 2000. The Rome race is a sister project with the New York City affiliate of the Komen Foundation. A second race will be run on August 13, in Frankfurt, Germany.

Dr. Masetti applauded the Foundation for extending its public education efforts to Europe. “One of the major challenges globally is certainly education. Women need to know more about breast cancer. We look to the United States, where now every woman is willing to stand up and speak about breast cancer. This is the model we want to bring to other countries of the world,” he said.

Like their US counterparts, international affiliates are organized by groups of local volunteers who must complete a detailed affiliate application, followed by a comprehensive community needs assessment.

In addition, the applicant must demonstrate significant support for the Foundation’s mission from the local medical and scientific community, as well as from the business community and civic organizations. The applicant is also asked to make initial recommendations for awareness and education programs.

All of the money raised by these international affiliates will stay in their respective countries to support breast cancer research, education, screening, and treatment programs, Ms. Braun said.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content